Related Experiment Videos
Hairy cell leukemia: treatment prospects
1Repatriation General Hospital, Daws Road, Daw Park, South Australia 5041. prabha.seshadri@rgh.sa.gov.au
Expert Review of Anticancer Therapy
|July 13, 2002
Summary
Recent advances in hairy cell leukemia management, including alpha-interferon and purine analogs, have significantly improved patient outcomes. The genetic cause of this B-cell disorder remains unidentified.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Hairy cell leukemia is a chronic, indolent B-cell lymphoproliferative disorder.
- Historically, the prognosis for hairy cell leukemia was poor.
- Advances in treatment have transformed patient outcomes.
Purpose of the Study:
- To review recent advancements in the management of hairy cell leukemia.
- To highlight the impact of new therapeutic agents on patient prognosis.
Main Methods:
- Review of literature on hairy cell leukemia management.
- Analysis of treatment outcomes with alpha-interferon, purine analogs, and monoclonal antibodies/immunotoxins.
Main Results:
- Introduction of alpha-interferon has improved outcomes.
- Purine analogs offer effective treatment options.
- Recombinant monoclonal antibodies and immunotoxins further enhance therapeutic success.
Conclusions:
- Modern therapies have dramatically improved the prognosis for hairy cell leukemia.
- The underlying genetic defect in hairy cell leukemia requires further investigation.